Proteus Digital Health
$1.5Bpaper valuation
// OVERVIEW
Proteus Digital Health was worth $1.5 billion proving that sensors small enough to swallow could track medication compliance — then filed for bankruptcy in 2020 and sold its assets for $15 million, which is what happens when you build a healthcare company that requires patients to eat microchips daily and insurers to pay for the privilege.
// HQ
Redwood City, United States
// STATUS
PRIVATE
// FOUNDED
2001
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
digital health
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Proteus built ingestible sensors — silicon chips smaller than a grain of sand embedded in pills that transmitted confirmation signals when dissolved by stomach acid. The chips communicated with adhesive skin patches that relayed data to smartphones, creating an end-to-end medication adherence tracking system that worked technically and failed commercially.
// WOWLS ASSESSMENT
The company raised $500 million across 15 years, achieved FDA approval for its digital pill system in 2017, signed partnerships with Otsuka Pharmaceutical, and went bankrupt three years later because nobody would pay for it at scale. Hospitals valued medication compliance monitoring at approximately $0 per patient when presented with actual invoices. The technology was real — Proteus could track whether patients took their pills with 90% accuracy — but the business model required convincing healthcare systems to spend hundreds of dollars per month on adherence monitoring when generic medications cost $4. COVID-19 accelerated the collapse by eliminating pilot programs, but the fundamental problem predated the pandemic: asking sick people to swallow daily microchips is a harder adoption challenge than any regulatory pathway.
// WHY WOWLS HUNTS THIS
Perfect case study in confusing technical feasibility with commercial viability. The FDA approval was the beginning of the failure, not the validation — regulatory clearance meant the hard work of convincing payers to reimburse hundreds of dollars monthly for generic medication tracking had finally begun, and Proteus discovered there was no market at the price required to sustain operations.
// VALUATION NOTE
Peak $1.5B valuation based on 2015 Series E. Bankruptcy filed June 2020. Assets acquired by Otsuka Pharmaceutical for approximately $15M in August 2020 — a 99% destruction of enterprise value.
VERDICT: ZOMBIECORN — THE COMPANY RAISED $500 MILLION TO PROVE THAT MEDICATION ADHERENCE TECHNOLOGY WORKS AND $0 TO PROVE THAT ANYONE WILL PAY FOR IT
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Proteus Digital Health.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Proteus Digital Health?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN